Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01542047 · ClinicalTrials.gov registry record · Phase 1
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01542047 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 3 participants.
The verdict
NCT01542047, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to investigate the possibility that use of two similar but distinct drugs used together in treatment of advanced cancer might prove less toxic than either agent used alone, because dosages can be reduced for each agent. This is a phase I study that is designed to measure the frequency and levels of specific side effects when Carboplatin and Pazopanib are used in combination in advanced cancer patients. The possibility that anti-tumor activity will occur is also going to be investigated.
Interventions
- DRUG Carboplatin
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01542047
The ClinicalTrials.gov registry entry for NCT01542047 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01542047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01542047 about?
NCT01542047 is a clinical study titled "A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies". This study is designed to investigate the possibility that use of two similar but distinct drugs used together in treatment of advanced cancer might prove less toxic than either agent used alone, because dosages can be reduced for each agent. This is a phase I study that is designed to measure the f...
What is the current status of trial NCT01542047?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01542047?
The interventions under investigation include: Carboplatin (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01542047?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.